CELG stock forecast
Our latest prediction for Celgene Corp.'s stock price was made on the May 9, 2018 when the stock price was at 82.80$.
In the short term (2weeks), CELG's stock price should outperform the market by 1.93%. During that period the price should oscillate between -3.97% and +4.85%.
In the medium term (3months), CELG's stock price should outperform the market by 1.75%. During that period the price should oscillate between -8.48% and +12.59%.Get email alerts
About Celgene Corp.
Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include REVLIMID, POMALYST, IMNOVID, OTEZLA, ABRAXANE, and VIDAZA. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.
At the moment the company generates 14727M USD in revenues.
On its last earning announcement, the company reported a profit of 3.94$ per share.
The book value per share is 4.88$
Three months stock forecastMay 9, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|